164 related articles for article (PubMed ID: 20477974)
1. Induction therapy in pediatric kidney transplant recipients discharged with a triple drug immunosuppressive regimen.
Sampaio MS; Poommipanit N; Kuo HT; Reddy PN; Cho YW; Shah T; Bunnapradist S
Pediatr Transplant; 2010 Sep; 14(6):770-8. PubMed ID: 20477974
[TBL] [Abstract][Full Text] [Related]
2. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation.
Taber DJ; Weimert NA; Henderson F; Lin A; Bratton CF; Chavin KD; Baliga PK
Transplant Proc; 2008 Dec; 40(10):3401-7. PubMed ID: 19100399
[TBL] [Abstract][Full Text] [Related]
4. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
6. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S
Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
[TBL] [Abstract][Full Text] [Related]
9. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
[TBL] [Abstract][Full Text] [Related]
10. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
13. Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients.
Palanisamy AP; Al Manasra AR; Pilch NA; Dowden JE; Nadig SN; McGillicuddy JW; Baliga PK; Chavin KD; Taber DJ
Clin Transplant; 2015 Mar; 29(3):222-6. PubMed ID: 25557762
[TBL] [Abstract][Full Text] [Related]
14. Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients.
Taber DJ; McGillicuddy JW; Bratton CF; Rohan VS; Nadig S; Dubay D; Baliga PK
Ann Surg; 2017 Sep; 266(3):450-456. PubMed ID: 28654544
[TBL] [Abstract][Full Text] [Related]
15. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
[TBL] [Abstract][Full Text] [Related]
16. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies.
Crins ND; Röver C; Goralczyk AD; Friede T
Pediatr Transplant; 2014 Dec; 18(8):839-50. PubMed ID: 25283839
[TBL] [Abstract][Full Text] [Related]
18. Rabbit antithymocyte globulin induction therapy in adult renal transplantation.
Hardinger KL
Pharmacotherapy; 2006 Dec; 26(12):1771-83. PubMed ID: 17125438
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
[TBL] [Abstract][Full Text] [Related]
20. Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants.
Bunnapradist S; Takemoto SK
Transplant Proc; 2005 Mar; 37(2):889-91. PubMed ID: 15848566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
